Objective—To evaluate association of various treatments
for immune-mediated hemolytic anemia with
survival to discharge in dogs.
Design—Retrospective cross-sectional analysis.
Animals—88 dogs with idiopathic immune-mediated
Procedure—Medical records of dogs with immunemediated
hemolytic anemia treated between August
1989 and August 1999 were examined. Survival to
discharge, PCV at referral, autoagglutination, and drug
treatment and dosage were recorded.
Results—Treatments included administration of prednisone,
dexamethasone, azathioprine, danazol,
cyclosporine, cyclophosphamide, bovine hemoglobin
solution, and human immunoglobulin. Overall mortality
rate was 50.5%. Significant associations with death
were not detected for use of azathioprine, cyclosporine,
danazol, or human immunoglobulin. A significant
difference in mortality rate was not detected
between use of multiple immunosuppressive drug
treatments and use of single immunosuppressive
drugs. Use of cyclophosphamide and bovine hemoglobin
solution were associated with significant
increases in relative risk of death.
Conclusions and Clinical Relevance—Results suggest
that use of cyclophosphamide and bovine hemoglobin
solution in treatment of idiopathic immunemediated
hemolytic anemia may be associated with
increased risk of death. (J Am Vet Med Assoc